JP2003528918A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003528918A5 JP2003528918A5 JP2001572106A JP2001572106A JP2003528918A5 JP 2003528918 A5 JP2003528918 A5 JP 2003528918A5 JP 2001572106 A JP2001572106 A JP 2001572106A JP 2001572106 A JP2001572106 A JP 2001572106A JP 2003528918 A5 JP2003528918 A5 JP 2003528918A5
- Authority
- JP
- Japan
- Prior art keywords
- dioxopiperidine
- phthalimido
- succimido
- allyl
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 0 *C(CCC(N1*)=O)C1=O Chemical compound *C(CCC(N1*)=O)C1=O 0.000 description 1
- FOCJPXHBCBSSFA-UHFFFAOYSA-N 2-(1-benzyl-2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(C1=O)CCC(=O)N1CC1=CC=CC=C1 FOCJPXHBCBSSFA-UHFFFAOYSA-N 0.000 description 1
- WJTRZXRQSAMCIM-UHFFFAOYSA-N 2-(1-ethyl-2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound O=C1N(CC)C(=O)CCC1N1C(=O)C2=CC=CC=C2C1=O WJTRZXRQSAMCIM-UHFFFAOYSA-N 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- CNMOHEDUVVUVPP-UHFFFAOYSA-N piperidine-2,3-dione Chemical compound O=C1CCCNC1=O CNMOHEDUVVUVPP-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19398100P | 2000-03-31 | 2000-03-31 | |
| US09/193,981 | 2000-03-31 | ||
| PCT/US2001/010581 WO2001074362A1 (en) | 2000-03-31 | 2001-03-30 | Inhibition of cyclooxygenase-2 activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003528918A JP2003528918A (ja) | 2003-09-30 |
| JP2003528918A5 true JP2003528918A5 (enExample) | 2008-05-29 |
Family
ID=22715841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001572106A Pending JP2003528918A (ja) | 2000-03-31 | 2001-03-30 | シクロオキシゲナーゼ−２活性の阻害 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20020022627A1 (enExample) |
| EP (1) | EP1272189A4 (enExample) |
| JP (1) | JP2003528918A (enExample) |
| KR (1) | KR20030003708A (enExample) |
| CN (1) | CN1420776A (enExample) |
| AU (1) | AU2001249755A1 (enExample) |
| CA (1) | CA2404152C (enExample) |
| MX (1) | MXPA02009665A (enExample) |
| NO (1) | NO20024627L (enExample) |
| NZ (1) | NZ521937A (enExample) |
| WO (1) | WO2001074362A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US20030013739A1 (en) * | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
| US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| NZ526683A (en) * | 2000-11-30 | 2008-03-28 | Childrens Medical Center | Synthesis of 4-amino-thalidomide and its enantiomers that are suitable for inhibiting angiogenesis |
| EP1389203B8 (en) * | 2001-02-27 | 2010-03-10 | The Governement of the United States of America, represented by The Secretary Department of Health and Human services | Analogs of thalidomide as angiogenesis inhibitors |
| USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| WO2003097040A1 (en) * | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
| US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
| US7842691B2 (en) * | 2002-10-15 | 2010-11-30 | Celgene Corporation | Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US8034831B2 (en) * | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| KR20090048520A (ko) | 2002-11-06 | 2009-05-13 | 셀진 코포레이션 | 암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨 억제 약물의 사용 방법 및 그 조성물 |
| US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
| US9006267B2 (en) | 2002-11-14 | 2015-04-14 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US20080027113A1 (en) * | 2003-09-23 | 2008-01-31 | Zeldis Jerome B | Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration |
| US7612096B2 (en) * | 2003-10-23 | 2009-11-03 | Celgene Corporation | Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline |
| EP1684758A4 (en) * | 2003-11-06 | 2009-02-18 | Celgene Corp | METHODS AND COMPOSITIONS USING THALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES |
| US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| MXPA06010699A (es) * | 2004-03-22 | 2006-12-15 | Celgene Corp | Metodos de usos y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades o alteraciones de la piel. |
| US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| CN1972686A (zh) * | 2004-04-14 | 2007-05-30 | 细胞基因公司 | 选择性细胞因子抑制药在髓发育不良综合征中的用途 |
| CN1968695A (zh) * | 2004-04-14 | 2007-05-23 | 细胞基因公司 | 含有用于治疗和控制骨髓发育不良综合征的免疫调节化合物的组合物和使用方法 |
| JP2007533761A (ja) * | 2004-04-23 | 2007-11-22 | セルジーン・コーポレーション | 肺高血圧症を治療し管理するための、免疫調節性化合物の使用方法及び免疫調節性化合物を含む組成物 |
| CA2588597A1 (en) * | 2004-11-23 | 2006-06-01 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
| US20060270707A1 (en) * | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
| US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
| US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
| CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
| WO2009020590A1 (en) | 2007-08-07 | 2009-02-12 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
| US10034872B2 (en) | 2014-08-22 | 2018-07-31 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| CN106137986B (zh) * | 2015-03-09 | 2019-04-16 | 常州制药厂有限公司 | 一种沙利度胺片及其制备方法 |
| HUE065109T2 (hu) | 2015-06-26 | 2024-05-28 | Celgene Corp | Eljárások Kaposi-szarkóma vagy KSHV-indukált limfóma kezelésére immunomodulátor vegyületek alkalmazásával, valamint biomarkerek alkalmazása |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2830991A (en) * | 1954-05-17 | 1958-04-15 | Gruenenthal Chemie | Products of the amino-piperidine-2-6-dione series |
| US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) * | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) * | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| AU1531492A (en) * | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) * | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6114355A (en) * | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
| US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5731325A (en) * | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US5798368A (en) * | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| JP4214537B2 (ja) * | 1996-08-12 | 2009-01-28 | セルジーン コーポレーション | 新規な免疫治療薬とこの薬物を使用してサイトカインレベルを抵減する方法 |
| US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| US5874448A (en) * | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US6590243B2 (en) * | 1999-04-28 | 2003-07-08 | Sharp Laboratories Of America, Inc. | Ferroelastic lead germanate thin film and deposition method |
-
2001
- 2001-03-30 AU AU2001249755A patent/AU2001249755A1/en not_active Abandoned
- 2001-03-30 MX MXPA02009665A patent/MXPA02009665A/es active IP Right Grant
- 2001-03-30 KR KR1020027013123A patent/KR20030003708A/ko not_active Ceased
- 2001-03-30 EP EP01923016A patent/EP1272189A4/en not_active Withdrawn
- 2001-03-30 CN CN01807481A patent/CN1420776A/zh active Pending
- 2001-03-30 JP JP2001572106A patent/JP2003528918A/ja active Pending
- 2001-03-30 CA CA002404152A patent/CA2404152C/en not_active Expired - Fee Related
- 2001-03-30 NZ NZ521937A patent/NZ521937A/en not_active IP Right Cessation
- 2001-03-30 US US09/823,057 patent/US20020022627A1/en not_active Abandoned
- 2001-03-30 WO PCT/US2001/010581 patent/WO2001074362A1/en not_active Ceased
-
2002
- 2002-09-27 NO NO20024627A patent/NO20024627L/no not_active Application Discontinuation
-
2003
- 2003-10-07 US US10/680,606 patent/US20040077686A1/en not_active Abandoned
-
2006
- 2006-05-04 US US11/429,300 patent/US20060199819A1/en not_active Abandoned
-
2009
- 2009-02-19 US US12/388,609 patent/US20090156641A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002508362A5 (ja) | １−置換−１−アミノメチル−シクロアルカン誘導体（＝ガバペンチン類縁体） | |
| CA2530006A1 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
| JP2002540208A5 (enExample) | ||
| JP2002502874A5 (enExample) | ||
| JP2004523498A5 (enExample) | ||
| JP2004532810A5 (enExample) | ||
| JP2003531118A5 (enExample) | ||
| JP2002541233A5 (enExample) | ||
| CY1107850T1 (el) | Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους | |
| HUE048936T2 (hu) | Glikopirrolátot és egy béta2 adrenoreceptor agonistát tartalmazó gyógyszerkészítmény | |
| JP2002513793A5 (enExample) | ||
| PL1737847T3 (pl) | Nebiwolol i jego farmaceutycznie dopuszczalne sole, proces ich przygotowania i kompozycje farmaceutyczne nebiwololu | |
| BR0306292A (pt) | Composto de éster e uso medicinal do mesmo | |
| JP2002527474A5 (ja) | 躁病および双極性障害の治療のための医薬 | |
| GEP20115211B (en) | Terphenyl derivatives for treatment of alzheimer' s disease | |
| JP2005532372A5 (enExample) | ||
| JP2002520286A5 (enExample) | ||
| JP2008546770A5 (enExample) | ||
| JP2008512408A5 (enExample) | ||
| IL184116A0 (en) | Use of thiazolidinone derivatives as antiangiogenic agents | |
| JP2002506864A5 (enExample) | ||
| MY140410A (en) | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | |
| RU2010154417A (ru) | Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств | |
| JP2002541198A5 (ja) | 失禁治療用医薬組成物 | |
| JP2003512494A5 (enExample) |